Q3 2022 Results

Company overview Financial review 2022 priorities Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials Cardiovascular Immunology Neuroscience Oncology Leqvio® - siRNA (regulation of LDL-C) NCT04652726 ORION-16 (CKJX839C12301) References LeqvioⓇ - siRNA (regulation of LDL-C) NCT04659863 ORION-13 (CKJX839C12302) Hyperlipidemia, pediatrics Indication Hyperlipidemia, pediatrics Indication Phase Phase 3 Phase Phase 3 Patients 150 Patients 12 Primary Outcome Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 Primary Outcome Measures Measures Arms Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630 Arms Intervention Intervention Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol Target Patients (LDL-C) Read-out Milestone(s) 2025 Publication Design publication in Eur. J. Prev. Cardiol. Vol. 29, Feb. 2022; Presentation at EAS May-2022 48 Investor Relations | Q3 2022 Results Abbreviations Other Target Patients Read-out Milestone(s) Publication Percentage (%) change in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 Group 1: Inclisiran sodium 300mg on Days 1, 90, 270, placebo on Day 360, inclisiran sodium 300mg on Days 450 and 630. Group 2: Placebo on Days 1, 90, 270, inclisiran sodium 300mg on Days 360, 450 and 630. Adolescents (12 to less than 18 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDL-C) 2025 Design publication in Eur. J. Prev. Cardiol. Vol. 29, Feb. 2022; Presentation at EAS May-2022 NOVARTIS | Reimagining Medicine

View entire presentation